Ping An Biomedical Co., Ltd. income statement

In fiscal 2025, Ping An Biomedical Co., Ltd. reported revenue of $4.7m, down 61.1% on the year before, operating income of −$2.0m (a -43.1% margin) and net income of −$1.8m, or −$0.10 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Ping An Biomedical Co., Ltd.: income statement, annual
Fiscal year	2023Sept 2023	2024Sept 2024	2025Sept 2025
Revenue	12	12	5
Cost of revenue	11	11	5
Gross profit	1	1	0
Selling and marketing	0	0	0
General and administrative	0	1	1
Operating income	0	−0	−2
Interest expense	0	0	0
Income before tax	0	−0	−2
Income tax	−0	−0	0
Net income	−0	−0	−2
Diluted EPS	−$0.01	−$0.01	−$0.10
Diluted shares (average)	18m	18m	18m
EBITDA	0	0	−2

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: NTRP vs PASW PASW vs XELB PASW vs UZX

More: Consumer Discretionary sector, rankings of US companies

Figures from Ping An Biomedical Co., Ltd.'s SEC filings (10-K and 10-Q). How we read and check them: methodology and data sources. Not investment advice. Back to Ping An Biomedical Co., Ltd.